GlassScriptPhysician profile
Stacy L Johnson
NPI 1417907189
$8,327.72
in general payments reported to CMS, 2019-2025
57 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,707 · 2022: $3,009 · 2023: $1,951 · 2024: $206 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,462 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,461.96 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $995.84 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $441.41 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $435.20 | 2021-2022 | |
| Biogen, INC. | $432.27 | 2021-2023 | Vumerity, Tysabri, Spinraza |
| Emd Serono, INC. | $428.52 | 2021-2023 | Mavenclad |
| Celgene Corporation | $393.84 | 2021-2024 | Zeposia |
| Jazz Pharmaceuticals INC. | $366.36 | 2021-2025 | |
| Livanova USA, INC. | $357.13 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Amgen INC. | $329.96 | 2021-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $270.51 | 2021-2023 | Austedo Xr |
| Lilly USA, LLC | $251.54 | 2021-2023 | Reyvow, Emgality |
| Acadia Pharmaceuticals INC | $235.57 | 2021-2023 | Nuplazid |
| Ucb, INC. | $227.15 | 2021-2023 | Briviact |
| Neurelis, INC. | $187.65 | 2021-2023 | Valtoco |
| Alexion Pharmaceuticals, INC. | $181.30 | 2021-2023 | Ultomiris |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.